ARTV — Artiva Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1817241 ·
Last close
$7.67
Market Cap
$372.67M
52W High
$14.53
52W Low
$4.74
ADV30
612,391
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -24,430,000 | -23,516,000 | 105,955,000 | 20,955,000 | 18,108,000 |
| Dec 2025 | 0 | — | -21,932,000 | -20,772,000 | 130,940,000 | 26,701,000 | 20,970,000 |
| Sep 2025 | 0 | — | -22,897,000 | -21,528,000 | 148,862,000 | 25,508,000 | 19,638,000 |
| Jun 2025 | 0 | — | -22,810,000 | -21,254,000 | 169,391,000 | 28,468,000 | 20,350,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-76,751,000
Investing CF
$63,411,000
Financing CF
$9,000
CapEx
$-2,587,000
Dividends Paid
—
Buybacks
$-4,183,000
EPS Diluted TTM
$-3.50
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-330,549,000
Inventory
—
Receivables
$67,000
ST Investments
$81,307,000
EBIT TTM
$-89,810,000
Pretax Income TTM
$-83,865,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -89,810,000 | -83,865,000 | 130,940,000 | 20,970,000 | — | -76,751,000 |
| Dec 2024 | 251,000 | -67,282,000 | -58,179,000 | 209,581,000 | 22,940,000 | — | -55,032,000 |
| Dec 2023 | 33,492,000 | -30,671,000 | -32,766,000 | 105,114,000 | 267,129,000 | — | -47,430,000 |
| Dec 2022 | 4,931,000 | -59,829,000 | -60,976,000 | 133,054,000 | 273,750,000 | — | -50,829,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.81
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals, Inc | $377.28M | $4.00 | — |
| REPL | Replimune Group, Inc. | $379.83M | $4.60 | — |
| CCCC | C4 Therapeutics, Inc. | $385.88M | $3.49 | — |
| IPSC | Century Therapeutics, Inc. | $391.37M | $2.17 | — |
| CMPX | Compass Therapeutics, Inc. | $396.19M | $2.20 | — |
News headlines (Yahoo Finance, 1h cache)
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cel
2026-05-19 20:05 · Yahoo
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
2026-05-19 12:00 · Yahoo
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
2026-05-08 10:52 · Yahoo
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-08 10:31 · Yahoo
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
2026-05-08 10:30 · Yahoo
Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans?
2026-04-17 18:15 · Yahoo
Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham
2026-04-15 22:02 · Yahoo
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
2026-04-08 12:00 · Yahoo
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
2026-03-10 20:05 · Yahoo
Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update
2026-03-04 20:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.